



ASX ANNOUNCEMENT

13 February 2015

Change of Share Registry

Melbourne, Australia; 13 February 2015: The Board of stem cell and regenerative medicine company, Cynata Therapeutics Limited (ASX: CYP), wishes to advise that responsibility for the maintenance of the Company's share register will be transferred to Automic Registry Services, effective from the start of business on Monday, 9 March 2015.

The new share registry contact details will be as follows.

Automic Registry Services

Telephone: 1300 288 664

Web Address: www.automic.com.au

Street Address:

Level 1
7 Ventnor Ave
WEST PERTH WA 6005

Postal Address:

PO Box 223
WEST PERTH WA 6872

Peter Webse

Company Secretary

About Cynata Therapeutics (ASX: CYP)

Cynata Therapeutics Ltd (ASX: CYP) is an Australian stem cell and regenerative medicine company that is developing a therapeutic stem cell platform technology, Cymerus™, originating from the University of Wisconsin-Madison, a world leader in stem cell research. The proprietary Cymerus™ technology seeks to address a critical shortcoming in existing methods of production of mesenchymal stem cells (MSCs) for therapeutic use, which is the ability to achieve economic manufacture at commercial scale. Cymerus™ does so through the production of a particular type of MSC precursor, called a mesenchymoangioblast (MCA). The Cymerus™ MCA platform provides a source of MSCs that is independent of donor limitations and provides a potential "off-the-shelf" stem cell platform for therapeutic product use, with a pharmaceutical business model and economies of scale. This has the potential to create a new standard in the emergent arena of stem cell therapeutics and provides both a unique differentiator and an important competitive position.